FIGURE 6.

Activity of the domain-minimized H2 relaxin analogues on the RXFP1 receptor. A, competition binding results of H2 relaxin and the domain-minimized analogues, H2-(A5–24)(B7–24) and H2-(A7–24)(B7–24), with and without pyroglutamate (<Glu) in HEK-293T cells stably expressing the RXFP1 receptor using Eu³⁺-labeled H2 relaxin as the ligand. Data are expressed as percentage of specific binding and are pooled data from at least three experiments performed in triplicate. B, cAMP activity of H2 relaxin and the domain-minimized analogues, H2-(A5–24)(B7–24) and H2-(A7–24)(B7–24), in HEK-293T cells expressing the RXFP1 receptor using a pCRE-galactosidase reporter gene system. Data are expressed as percentage of maximum H2 relaxin-stimulated cAMP response and are pooled data from at least three experiments performed in triplicate. C, competition binding results of H2 relaxin and the domain minimized analogues, H2-(A4–24)(B7–24) and H2-(A5–24)(B7–24), with and without C-terminal amidation in HEK-293T cells stably expressing the RXFP1 receptor using Eu³⁺-labeled H2 relaxin as the competitive ligand. Data are expressed as percentage of specific binding and are pooled data from at least three experiments performed in triplicate. D, cAMP activity of H2 relaxin and the domain-minimized analogues, H2-(A4–24)(B7–24) and H2-(A5–24)(B7–24) with/without C-terminal amidation, in HEK-293T cells expressing the RXFP1 receptor using a pCRE-galactosidase reporter gene system. Data are expressed as percentage of maximum H2 relaxin-stimulated cAMP response and are pooled data from at least three experiments performed in triplicate.